Haya Taitel
Director/Board Member at ENTERA BIO LTD.
Net worth: 40 500 $ as of 2024-05-30
Profile
Haya Taitel is an Independent Director at Entera Bio Ltd.
since 2023.
Previously, she worked as the Chief Commercial Officer at Kadmon Holdings, Inc. from 2018 to 2021.
She completed her undergraduate degree at The Hebrew University of Jerusalem and her graduate degree at Temple University School of Pharmacy.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ENTERA BIO LTD.
0.05% | 2024-05-22 | 18,000 ( 0.05% ) | 40 500 $ | 2024-05-30 |
Haya Taitel active positions
| Companies | Position | Start |
|---|---|---|
| ENTERA BIO LTD. | Director/Board Member | 2023-06-06 |
Former positions of Haya Taitel
| Companies | Position | End |
|---|---|---|
| KADMON HOLDINGS, INC. | Corporate Officer/Principal | 2021-10-31 |
Training of Haya Taitel
| The Hebrew University of Jerusalem | Undergraduate Degree |
| Temple University School of Pharmacy | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ENTERA BIO LTD. | Health Technology |
| Private companies | 1 |
|---|---|
Kadmon Holdings, Inc.
 Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Haya Taitel
